TRACON (TCON) - Narx-foyda koeffitsiyenti

TRACON (TCON) brendining ramzi va logotipi

TRACON Pharmaceuticals (TCON) noyob o'smalarga qarshi kurashish uchun monoklonal antitelalarni ishlab chiqish, royalti va oldindan to'lovlarni olish orqali daromad keltiradi. Kompaniya global sherikliklar orqali sinov xarajatlarini minimallashtiradi. Biroq, dori vositalarining yakuniy bosqichdagi sinovlarining muvaffaqiyatsizligi bankrotlik va listingdan chiqarilish xavfini yuzaga keltirdi. Baholash vositasi bo'lib xizmat qiluvchi ushbu narxlar grafigi (separate_pe) 2.20 qiymatini ko'rsatib, emitentning joriy moliyaviy holatini ifodalaydi.

TCON TRACON Pharmaceuticals Inc.: Narxning foydaga nisbati 04.07.2022 - 29.06.2024 oraligʻida

TRACON Pharmaceuticals kompaniyasining tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya narxi traconpharma.com|TCON - Tahlilchilar konsensus prognozi
- bozor kapitallashuvi ko'rsatkichlari:
Bozor bahosi TRACON Pharmaceuticals, Inc.|TCON - Kompaniyaning to‘liq qiymati
- balans bo'yicha xususiy kapital ma'lumotlari:
Bitta aksiya hisobiga sof aktivlar qiymati TRACON Pharmaceuticals|TCON - Kompaniyaning balans qiymati|Kapitallashuvning balans qiymatiga nisbati traconpharma.com|TCON - Kompaniyaning yakuniy aktivlari
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Barcha qarzlarning o‘z mablag‘lariga nisbati TRACON Pharmaceuticals|TCON - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli majburiyatlarning o'z kapitaliga nisbati TRACON Pharmaceuticals, Inc|TCON - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati TRACON Pharmaceuticals, Inc.|TCON - Kompaniyaning uzoq muddatli qarzlari|Kompaniyaning qisqa muddatli qarzlari TRACON Pharmaceuticals|Oraliq qoplash koeffitsiyenti traconpharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
TCON - Kompaniyaning sof foydasi|Kelajakdagi foyda TRACON Pharmaceuticals|TCON - P/E multiplikatori|Forvard P/E multiplikatori TRACON Pharmaceuticals Inc.|TCON - PEG multiplikatori|Korxona qiymatining foizlar, soliqlar va amortizatsiyadan oldingi foydaga nisbati koeffitsiyenti TRACON Pharmaceuticals, Inc.|TCON - EBITDA operatsion foydasi|So'nggi o'n ikki oy davomida bitta aksiya uchun sof foyda TRACON Pharmaceuticals|TCON - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi traconpharma.com|TCON - Bu yil bir aksiya uchun sof foyda o'sishi|Keyingi yilda bir aksiya uchun foydaning prognoz qilingan ortishi TRACON Pharmaceuticals
- realizatsiya hajmi va tushum ko'rsatkichlari:
TCON - Daromad va sotish hajmi|Kompaniyaning kelajakdagi savdosi traconpharma.com|TCON - P/S multiplikatori|Forvard narx/daromad multiplikatori TRACON Pharmaceuticals, Inc.
Kompaniyaning jamlanma tahlili:traconpharma.com - TCON
TRACON Pharmaceuticals Inc. yetakchi tovari

Professional aktivlarni tanlash biznesning haqiqiy daromadlariga nisbatan bozor qiymatini tahlil qilishdan boshlanadi. Ushbu metrika TRACON Pharmaceuticals (TCON) kapitalizatsiyasini uning yillik sof foydasi bilan bog'lab, qimmatbaholanganlik darajasini aniqlaydi. Kompaniyaning prognoz qilingan P/E ko'rsatkichini tahlil qilish orqali investor qimmatli qog'ozning sanoatdoshlariga nisbatan fundamental jozibadorligini baholaydi. TRACON Pharmaceuticals (TCON) uchun ushbu ko'rsatkich envafolimab uchun patentlangan teri ostiga yuborish usulining tijoratlashtirilishiga oid bozor kutganlarini aks ettiradi. Terapiyaning soddalashtirilgan shakliga o'tish daromadlar o'sishi va aktivning bahosini qayta ko'rib chiqish uchun imkoniyat yaratadi.

Muhim raqobatchilar

P/E multiplikatori Tempus AI Inc|P/E multiplikatori QGEN|Narx-foyda koeffitsiyenti Ionis Pharmaceuticals, Inc. IONS|Narxning foydaga nisbati Repligen Corp. RGEN|Avidity Corp (RNA) - Kapitalizatsiyaning foydaga nisbati|CRSP - Narxning foydaga nisbati|WGS (genedx.com) - Narx-foyda multiplikatori|RARE (Ultragenyx) - Narx-foyda koeffitsiyenti|Beam Therapeutics Inc - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Sarepta Therapeutics Inc|Twist Bioscience Corp - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori TXG|NTLA (intelliatx.com) - Kompaniya qiymatining sof foydaga nisbati|P/E multiplikatori STOK (Stoke Therapeutics, Inc.)|P/E multiplikatori BioLife Solutions Inc BLFS|WVE - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati MAZE (Maze Therapeutics Corp)|Sionna Therapeutics Inc (SION) - Narxning foydaga nisbati|Narx-foyda koeffitsiyenti primemedicine.com|TSHA (Taysha Gene Therapies, Inc.) - P/E multiplikatori|P/E multiplikatori uniQure NV|P/E multiplikatori MGTX|Narx-foyda koeffitsiyenti REGENXBIO Corp RGNX|P/E multiplikatori SLDB (Solid Biosciences Inc.)|ocugen.com (OCGN) - Kapitalizatsiyaning foydaga nisbati|PACB: Narx-foyda koeffitsiyenti|BNTC - P/E multiplikatori|DSGN (Design Pharma) - Narx-foyda koeffitsiyenti|RCKT: Bozor narxining sof foydaga nisbati|FDMT (4D Molecular Therapeutics) - P/E multiplikatori|Lexeo (LXEO) - Biznesning o‘zini qoplash muddati|P/E multiplikatori KRRO|Narx-foyda koeffitsiyenti Editas Medicine Inc EDIT|P/E multiplikatori SLN (Silence Therapeutics Inc.)|P/E multiplikatori ProQR PRQR|CDXS - Narxning foydaga nisbati|SGMO: Narxning foydaga nisbati|nautilus.bio (NAUT) - Narxning foydaga nisbati|MGX - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti DTIL|GBIO (Generation Bio Corp) - Bozor narxining sof foydaga nisbati|P/E multiplikatori BOLD|Narx-foyda koeffitsiyenti exicuretx.com XCUR|Narxning foydaga nisbati Imunon IMNN|Phio Pharmaceuticals Corp (PHIO) - Kapitalizatsiyaning foydaga nisbati|MBIO - Narxning foydaga nisbati|RNAZ (TransCode Therapeutics) - Narx-foyda multiplikatori|BNGO: P/E multiplikatori|Narx-foyda multiplikatori APDN|Narxning foydaga nisbati bluebird bio|Narx-foyda multiplikatori IPA (ImmunoPrecise)|P/E multiplikatori OMGA|P/E multiplikatori Singular Genomics Corp (OMIC)|Regulus Therapeutics - Narx-foyda koeffitsiyenti|Bozor narxining sof foydaga nisbati SYRS (syros.com)|TBIO - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati UBX (Unity Biotechnology Inc.)